Showing results (281-290 of 292) with videos related to

Sort By:
Pageof 30
Annals of Internal Medicine|December 1, 1993
The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthmaE Israel, P Rubin, J P Kemp, et al.
Chest|April 11, 2001
The utility of peak flow, symptom scores, and beta-agonist use as outcome measures in asthma clinical researchF T Leone, E A Mauger, S P Peters, et al.
JAMA|May 23, 2001
Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trialR F Lemanske, C A Sorkness, E A Mauger, et al.
JAMA|May 23, 2001
Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trialS C Lazarus, H A Boushey, J V Fahy, et al.
American Journal of Respiratory and Critical Care Medicine|May 24, 2001
Safety and reproducibility of sputum induction in asthmatic subjects in a multicenter studyJ V Fahy, H A Boushey, S C Lazarus, et al.
American Journal of Respiratory and Critical Care Medicine|November 14, 1997
An evaluation of colchicine as an alternative to inhaled corticosteriods in moderate asthma. National Heart, Lung, and Blood Institute's Asthma Clinical Research NetworkJ E Fish, S P Peters, C V Chambers, et al.
The Journal of Clinical Investigation|March 1, 1997
Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcriptionK H In, K Asano, D Beier, et al.
American Journal of Respiratory and Critical Care Medicine|July 21, 2000
The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthmaE Israel, J M Drazen, S B Liggett, et al.
International Archives of Allergy and Immunology|April 18, 2001
Effect of polymorphism of the beta(2)-adrenergic receptor on response to regular use of albuterol in asthmaE Israel, J M Drazen, S B Liggett, et al.
Stroke|September 30, 2025
Artificial Intelligence and Novel Trial Designs for Acute Ischemic Stroke: Opportunities and ChallengesJoseph P Broderick, Eva A Mistry, Paul M Wechsler, et al.
Pageof 30